Zaki Sellam is an experienced C-level biotech executive, with over two decades of experience and leadership in cancer/immunology drug discovery, translational medicine, clinical development, biotech startups, and fostering strategic alliances between prominent pharmaceutical companies and academic institutions. Mr. Sellam has raised approximately $100 million in equity financing in this sector. In addition to his role as CEO of Landmark BioVentures AG, he also serves as Executive Chairman to each of LBV Nexus companies.

Previously, Mr. Sellam was Founder and CEO of Avicenna Oncology GmbH, an Antibody Drug Conjugate start up located in Basel (2014-2019). Mr. Sellam also advises start-up companies, (including Iome Bio, Harvard spin off), Tech Transfer Accelerators and pharma companies (including OM Pharma) through his strategic consulting firm ESN Life Sciences GmbH (2011-present).

Mr. Sellam earned an MS in Biotechnology Engineering from the National School of Biotechnology in Bordeaux, France (2002) and an MBA from the Institute of Business Administration in Poitiers, France (2007).

Jacques Bauer is an experienced C-level biotech executive with over 35 years of experience and leadership in the pharmaceutical industry. He has held positions including Head of Research, Head of Research & Development and Head of Intellectual Property at several companies including Laboratoires OM (1985-1995), OM Pharma (1995-2009), Galenica (2009-2012), and Vifor Pharma (2012-2020).

Dr. Bauer is Founder and CEO of Inventuri Development (2021-present), a consultancy company advising on intellectual property and technical support issues in the life sciences and medicinal chemistry industries, located in Saint-Prex, Switzerland. In addition to his role as CDSO of Landmark BioVentures AG, he also serves as Chief Scientific Officer at Elikya Therapeutics and Duhn Therapeutics.

His professional achievements in medicinal chemistry include the successful development of small innovative first in class synthetic drugs from discovery to clinical level, and leading the development and industrial scaling-up of biologicals to market. Dr. Bauer’s project management experience encompasses matters related to intellectual property, chemistry, preclinical sciences, pharmacokinetics and early clinical stages in cancer and immunology.

Dr. Bauer earned an MS in Biology from University of Lausanne (1980) and a PhD in Medicinal and Pharmaceutical Chemistry from University of Lausanne (2001). Additionally, Dr. Bauer received intellectual property and industrial property law training from Centre Paul Roubier (2006).

Dr. Samson Fung is an experienced clinical MD and C-level biotech executive, with over 30 years of experience and leadership in oncology/immunology, clinical development, translational medicine, regulatory affairs (FDA and EMA) and advising biotechs in startup/advanced stages. Dr. Fung is Founder/Chief Medical Officer of Susavox Investments GmbH (2018-present) and was previously Founder/Chief Executive Officer of Volvox Therapeutics GmbH (2013-2018); both are oncology biotech startup companies based in Munich and Cambridge, Massachusetts. As Chief Medical Officer of Landmark BioVentures AG, he provides clinical development and clinical strategy leadership and trial oversight to each of LBV nexus companies.

Dr. Fung is Chief Medical Officer/Board Member at Molecure SA, Warsaw, Poland (WSE: MOC) (2022-present). Since 2008, Dr. Fung has advised companies such as Micromet, Roche, Novartis, Pharmacia/Pfizer, Novo Nordisk, AstraZeneca, Iome (affiliated with Harvard Medical School), and organizations such as Inhatarget SA in Belgium, BioM (Munich), and Simbec-Orion (based in UK and France), where he is also Member of the Scientific Advisory Board. He has been involved in more than 20 due diligence projects leading to in-/out-licensing of compounds in early and late-stage development.

Dr. Fung earned an MD from the University of Freiburg, Germany (1984) and Board Certification in internal medicine with sub-specialization in oncology and hematology (1992). He spent more than 8 years in academic teaching hospitals practicing general internal medicine, gastroenterology, nephrology and hemato-and medical oncology.

• Associate professor at EPHE, leading research on cancer immunotherapy
• Key contributor to the scientific foundation of DHN198

• Director of Centre Georges François Leclerc, a leading cancer research and treatment institute in Dijon, France
• Expert in oncology clinical trials and cancer immunotherapy